KR20030029111A - 신규 섬유아세포 성장 인자 (fgf23) 및 그의 이용 방법 - Google Patents
신규 섬유아세포 성장 인자 (fgf23) 및 그의 이용 방법 Download PDFInfo
- Publication number
- KR20030029111A KR20030029111A KR10-2003-7000821A KR20037000821A KR20030029111A KR 20030029111 A KR20030029111 A KR 20030029111A KR 20037000821 A KR20037000821 A KR 20037000821A KR 20030029111 A KR20030029111 A KR 20030029111A
- Authority
- KR
- South Korea
- Prior art keywords
- fgf23
- nucleic acid
- polypeptide
- disease
- mammal
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 139
- 102000018233 Fibroblast Growth Factor Human genes 0.000 title description 3
- 108050007372 Fibroblast Growth Factor Proteins 0.000 title description 3
- 229940126864 fibroblast growth factor Drugs 0.000 title description 2
- 108090000569 Fibroblast Growth Factor-23 Proteins 0.000 claims abstract description 611
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 197
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 181
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 181
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 142
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 107
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 107
- 201000010099 disease Diseases 0.000 claims abstract description 104
- 230000035772 mutation Effects 0.000 claims abstract description 83
- 230000003553 hypophosphatemic effect Effects 0.000 claims abstract description 63
- 230000004071 biological effect Effects 0.000 claims abstract description 38
- 208000029078 coronary artery disease Diseases 0.000 claims abstract description 8
- 208000007442 rickets Diseases 0.000 claims abstract description 6
- 201000004624 Dermatitis Diseases 0.000 claims abstract description 4
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 4
- 102000004042 Fibroblast Growth Factor-23 Human genes 0.000 claims abstract 85
- 210000004027 cell Anatomy 0.000 claims description 138
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 118
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 101
- 241000124008 Mammalia Species 0.000 claims description 96
- 230000014509 gene expression Effects 0.000 claims description 89
- 239000000203 mixture Substances 0.000 claims description 82
- 229920001184 polypeptide Polymers 0.000 claims description 78
- 201000003674 autosomal dominant hypophosphatemic rickets Diseases 0.000 claims description 63
- 229910019142 PO4 Inorganic materials 0.000 claims description 58
- 239000010452 phosphate Substances 0.000 claims description 58
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 58
- 150000001875 compounds Chemical class 0.000 claims description 56
- 239000003153 chemical reaction reagent Substances 0.000 claims description 53
- 239000013598 vector Substances 0.000 claims description 46
- 150000001413 amino acids Chemical group 0.000 claims description 40
- 239000012634 fragment Substances 0.000 claims description 40
- 108020004999 messenger RNA Proteins 0.000 claims description 39
- 206010028980 Neoplasm Diseases 0.000 claims description 36
- 230000001965 increasing effect Effects 0.000 claims description 35
- 239000003112 inhibitor Substances 0.000 claims description 35
- 208000005072 Oncogenic osteomalacia Diseases 0.000 claims description 31
- 239000003937 drug carrier Substances 0.000 claims description 31
- 230000000692 anti-sense effect Effects 0.000 claims description 30
- 230000000295 complement effect Effects 0.000 claims description 30
- 241001465754 Metazoa Species 0.000 claims description 28
- 230000001105 regulatory effect Effects 0.000 claims description 27
- 239000000523 sample Substances 0.000 claims description 27
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 26
- 102000053642 Catalytic RNA Human genes 0.000 claims description 24
- 108090000994 Catalytic RNA Proteins 0.000 claims description 24
- 108091092562 ribozyme Proteins 0.000 claims description 24
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 22
- 239000012472 biological sample Substances 0.000 claims description 22
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 21
- 102000005962 receptors Human genes 0.000 claims description 20
- 208000005050 Familial Hypophosphatemic Rickets Diseases 0.000 claims description 17
- -1 antibodies Proteins 0.000 claims description 17
- 239000004475 Arginine Substances 0.000 claims description 16
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 16
- 208000000740 hypophosphatemic bone disease Diseases 0.000 claims description 16
- 230000009261 transgenic effect Effects 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 14
- 208000004434 Calcinosis Diseases 0.000 claims description 13
- 230000002308 calcification Effects 0.000 claims description 13
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 12
- 210000004369 blood Anatomy 0.000 claims description 12
- 239000008280 blood Substances 0.000 claims description 12
- 201000006370 kidney failure Diseases 0.000 claims description 12
- 230000001613 neoplastic effect Effects 0.000 claims description 12
- 210000002700 urine Anatomy 0.000 claims description 12
- 206010058314 Dysplasia Diseases 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 7
- 208000031213 Epidermal nevus syndrome Diseases 0.000 claims description 7
- 206010029148 Nephrolithiasis Diseases 0.000 claims description 7
- 239000011575 calcium Substances 0.000 claims description 7
- 229910052791 calcium Inorganic materials 0.000 claims description 7
- 230000008021 deposition Effects 0.000 claims description 7
- 230000003176 fibrotic effect Effects 0.000 claims description 7
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 claims description 6
- 210000001367 artery Anatomy 0.000 claims description 6
- 208000014092 hereditary hypophosphatemic rickets Diseases 0.000 claims description 6
- 210000004872 soft tissue Anatomy 0.000 claims description 6
- 108010070675 Glutathione transferase Proteins 0.000 claims description 5
- 102000005720 Glutathione transferase Human genes 0.000 claims description 5
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 5
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 5
- 239000005090 green fluorescent protein Substances 0.000 claims description 5
- 229910052751 metal Inorganic materials 0.000 claims description 5
- 239000002184 metal Substances 0.000 claims description 5
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 claims description 4
- 239000000816 peptidomimetic Substances 0.000 claims description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 3
- 108091000080 Phosphotransferase Proteins 0.000 claims description 3
- 230000015556 catabolic process Effects 0.000 claims description 3
- 238000006731 degradation reaction Methods 0.000 claims description 3
- 102000020233 phosphotransferase Human genes 0.000 claims description 3
- 241000712461 unidentified influenza virus Species 0.000 claims description 3
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 230000007812 deficiency Effects 0.000 claims description 2
- 230000009368 gene silencing by RNA Effects 0.000 claims description 2
- 238000002405 diagnostic procedure Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 230000004936 stimulating effect Effects 0.000 abstract 2
- 102100024802 Fibroblast growth factor 23 Human genes 0.000 description 518
- 235000018102 proteins Nutrition 0.000 description 101
- 108020004414 DNA Proteins 0.000 description 59
- 239000004480 active ingredient Substances 0.000 description 43
- 239000008194 pharmaceutical composition Substances 0.000 description 36
- 125000003729 nucleotide group Chemical group 0.000 description 35
- 235000001014 amino acid Nutrition 0.000 description 33
- 229940024606 amino acid Drugs 0.000 description 32
- 239000002773 nucleotide Substances 0.000 description 32
- 102000040430 polynucleotide Human genes 0.000 description 30
- 108091033319 polynucleotide Proteins 0.000 description 30
- 239000002157 polynucleotide Substances 0.000 description 30
- 238000012360 testing method Methods 0.000 description 28
- 238000009472 formulation Methods 0.000 description 27
- 210000001519 tissue Anatomy 0.000 description 27
- 125000003275 alpha amino acid group Chemical group 0.000 description 25
- 239000002299 complementary DNA Substances 0.000 description 25
- 210000002966 serum Anatomy 0.000 description 25
- 241000894007 species Species 0.000 description 25
- 239000000047 product Substances 0.000 description 23
- 238000001262 western blot Methods 0.000 description 23
- 241000699670 Mus sp. Species 0.000 description 22
- 238000004458 analytical method Methods 0.000 description 20
- 108020003175 receptors Proteins 0.000 description 19
- 102200045140 rs104894347 Human genes 0.000 description 18
- 208000024891 symptom Diseases 0.000 description 18
- 101100281001 Homo sapiens FGF23 gene Proteins 0.000 description 17
- 208000029663 Hypophosphatemia Diseases 0.000 description 16
- 108091034117 Oligonucleotide Proteins 0.000 description 16
- 239000004615 ingredient Substances 0.000 description 16
- 102200045135 rs28937882 Human genes 0.000 description 16
- 108091026890 Coding region Proteins 0.000 description 15
- 102000053602 DNA Human genes 0.000 description 15
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 15
- 235000009697 arginine Nutrition 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 229960002897 heparin Drugs 0.000 description 15
- 229920000669 heparin Polymers 0.000 description 15
- 238000000636 Northern blotting Methods 0.000 description 14
- 239000003636 conditioned culture medium Substances 0.000 description 14
- 239000013612 plasmid Substances 0.000 description 14
- 239000000843 powder Substances 0.000 description 14
- 102200045134 rs193922702 Human genes 0.000 description 14
- 238000003786 synthesis reaction Methods 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 13
- 238000009396 hybridization Methods 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 13
- 239000000463 material Substances 0.000 description 13
- 239000002609 medium Substances 0.000 description 13
- 239000003921 oil Substances 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- 230000002441 reversible effect Effects 0.000 description 13
- 201000005991 hyperphosphatemia Diseases 0.000 description 12
- 235000019198 oils Nutrition 0.000 description 12
- 238000012163 sequencing technique Methods 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 108700028369 Alleles Proteins 0.000 description 11
- 108091033380 Coding strand Proteins 0.000 description 11
- 101100281002 Mus musculus Fgf23 gene Proteins 0.000 description 11
- 208000031878 X-linked hypophosphatemia Diseases 0.000 description 11
- 208000035724 X-linked hypophosphatemic rickets Diseases 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 238000003776 cleavage reaction Methods 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 210000003734 kidney Anatomy 0.000 description 11
- 239000002245 particle Substances 0.000 description 11
- 238000003757 reverse transcription PCR Methods 0.000 description 11
- 230000007017 scission Effects 0.000 description 11
- 150000002148 esters Chemical class 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 210000004962 mammalian cell Anatomy 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 239000002270 dispersing agent Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 108091005461 Nucleic proteins Proteins 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000013604 expression vector Substances 0.000 description 8
- 210000001161 mammalian embryo Anatomy 0.000 description 8
- 238000010369 molecular cloning Methods 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 238000013518 transcription Methods 0.000 description 8
- 230000035897 transcription Effects 0.000 description 8
- 241001515965 unidentified phage Species 0.000 description 8
- 241000282412 Homo Species 0.000 description 7
- 241000699660 Mus musculus Species 0.000 description 7
- 108700026244 Open Reading Frames Proteins 0.000 description 7
- 108091005804 Peptidases Proteins 0.000 description 7
- 239000004365 Protease Substances 0.000 description 7
- 229920002684 Sepharose Polymers 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 7
- 210000002216 heart Anatomy 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 238000007911 parenteral administration Methods 0.000 description 7
- 239000003755 preservative agent Substances 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- 239000000375 suspending agent Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 238000011830 transgenic mouse model Methods 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 6
- 108700008625 Reporter Genes Proteins 0.000 description 6
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 6
- 108700019146 Transgenes Proteins 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000003599 food sweetener Nutrition 0.000 description 6
- 108020001507 fusion proteins Proteins 0.000 description 6
- 102000037865 fusion proteins Human genes 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 102000018358 immunoglobulin Human genes 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 239000003380 propellant Substances 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000003765 sweetening agent Substances 0.000 description 6
- 239000013603 viral vector Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 210000001124 body fluid Anatomy 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 239000003995 emulsifying agent Substances 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 230000013632 homeostatic process Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 239000012053 oil suspension Substances 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- 235000015112 vegetable and seed oil Nutrition 0.000 description 5
- 239000008158 vegetable oil Substances 0.000 description 5
- 239000000080 wetting agent Substances 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 108700024394 Exon Proteins 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 238000000137 annealing Methods 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 235000013601 eggs Nutrition 0.000 description 4
- 210000002257 embryonic structure Anatomy 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 210000003754 fetus Anatomy 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 230000013595 glycosylation Effects 0.000 description 4
- 238000006206 glycosylation reaction Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 229940072221 immunoglobulins Drugs 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 229940057995 liquid paraffin Drugs 0.000 description 4
- 239000006194 liquid suspension Substances 0.000 description 4
- 208000005368 osteomalacia Diseases 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 210000001236 prokaryotic cell Anatomy 0.000 description 4
- 238000000159 protein binding assay Methods 0.000 description 4
- 230000002685 pulmonary effect Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- 101710176159 32 kDa protein Proteins 0.000 description 3
- 108020005544 Antisense RNA Proteins 0.000 description 3
- 235000003911 Arachis Nutrition 0.000 description 3
- 244000105624 Arachis hypogaea Species 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- 102100031780 Endonuclease Human genes 0.000 description 3
- 108091008794 FGF receptors Proteins 0.000 description 3
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 3
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 description 3
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 description 3
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 description 3
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 description 3
- 101000829171 Hypocrea virens (strain Gv29-8 / FGSC 10586) Effector TSP1 Proteins 0.000 description 3
- 208000026350 Inborn Genetic disease Diseases 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 208000024556 Mendelian disease Diseases 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- 108020004566 Transfer RNA Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000007900 aqueous suspension Substances 0.000 description 3
- 239000008135 aqueous vehicle Substances 0.000 description 3
- 150000001484 arginines Chemical class 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 210000001612 chondrocyte Anatomy 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 239000007902 hard capsule Substances 0.000 description 3
- 201000011066 hemangioma Diseases 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 3
- 230000000849 parathyroid Effects 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 230000008488 polyadenylation Effects 0.000 description 3
- 238000001742 protein purification Methods 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 210000001550 testis Anatomy 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 210000001685 thyroid gland Anatomy 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 2
- 102100031910 A-kinase anchor protein 3 Human genes 0.000 description 2
- 235000019489 Almond oil Nutrition 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 102100023112 Dual specificity tyrosine-phosphorylation-regulated kinase 4 Human genes 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 102000003975 Fibroblast growth factor 3 Human genes 0.000 description 2
- 108090000378 Fibroblast growth factor 3 Proteins 0.000 description 2
- 102100028075 Fibroblast growth factor 6 Human genes 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102100035364 Growth/differentiation factor 3 Human genes 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101000774732 Homo sapiens A-kinase anchor protein 3 Proteins 0.000 description 2
- 101001049983 Homo sapiens Dual specificity tyrosine-phosphorylation-regulated kinase 4 Proteins 0.000 description 2
- 206010020590 Hypercalciuria Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 241000207836 Olea <angiosperm> Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 102100031440 Probable polypeptide N-acetylgalactosaminyltransferase 8 Human genes 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 208000002847 Surgical Wound Diseases 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 239000008168 almond oil Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 239000000305 astragalus gummifer gum Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 210000002459 blastocyst Anatomy 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 238000012875 competitive assay Methods 0.000 description 2
- 239000007859 condensation product Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000010363 gene targeting Methods 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 108010023260 immunoglobulin Fv Proteins 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 239000006193 liquid solution Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 238000004091 panning Methods 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000012130 whole-cell lysate Substances 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- KUWPCJHYPSUOFW-SCWFEDMQSA-N (2r,3r,4s,5r)-2-(hydroxymethyl)-6-(2-nitrophenoxy)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)OC1OC1=CC=CC=C1[N+]([O-])=O KUWPCJHYPSUOFW-SCWFEDMQSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 108020005098 Anticodon Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
- 108091062157 Cis-regulatory element Proteins 0.000 description 1
- 102100029136 Collagen alpha-1(II) chain Human genes 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000027205 Congenital disease Diseases 0.000 description 1
- 208000029767 Congenital, Hereditary, and Neonatal Diseases and Abnormalities Diseases 0.000 description 1
- 208000009738 Connective Tissue Neoplasms Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 229930182847 D-glutamic acid Natural products 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 208000034423 Delivery Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000701832 Enterobacteria phage T3 Species 0.000 description 1
- 101100004352 Escherichia coli lacZ gene Proteins 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 description 1
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 description 1
- 108090000382 Fibroblast growth factor 6 Proteins 0.000 description 1
- 102100027681 Fructose-2,6-bisphosphatase TIGAR Human genes 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102100024185 G1/S-specific cyclin-D2 Human genes 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108010090293 Growth Differentiation Factor 3 Proteins 0.000 description 1
- 102100040892 Growth/differentiation factor 2 Human genes 0.000 description 1
- 101000771163 Homo sapiens Collagen alpha-1(II) chain Proteins 0.000 description 1
- 101001060265 Homo sapiens Fibroblast growth factor 6 Proteins 0.000 description 1
- 101000651314 Homo sapiens Fructose-2,6-bisphosphatase TIGAR Proteins 0.000 description 1
- 101000980741 Homo sapiens G1/S-specific cyclin-D2 Proteins 0.000 description 1
- 101000893585 Homo sapiens Growth/differentiation factor 2 Proteins 0.000 description 1
- 101001023986 Homo sapiens Growth/differentiation factor 3 Proteins 0.000 description 1
- 101001023513 Homo sapiens NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9, mitochondrial Proteins 0.000 description 1
- 101000994626 Homo sapiens Potassium voltage-gated channel subfamily A member 1 Proteins 0.000 description 1
- 101001026192 Homo sapiens Potassium voltage-gated channel subfamily A member 6 Proteins 0.000 description 1
- 101000922698 Homo sapiens Probable polypeptide N-acetylgalactosaminyltransferase 8 Proteins 0.000 description 1
- 101000989787 Homo sapiens Protein C12orf4 Proteins 0.000 description 1
- 101001130243 Homo sapiens RAD51-associated protein 1 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000012741 Laemmli sample buffer Substances 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 101800000135 N-terminal protein Proteins 0.000 description 1
- 102100035383 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9, mitochondrial Human genes 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 101800001452 P1 proteinase Proteins 0.000 description 1
- 101150004854 PHEX gene Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 1
- 108091007643 Phosphate carriers Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 108010066816 Polypeptide N-acetylgalactosaminyltransferase Proteins 0.000 description 1
- 102100034368 Potassium voltage-gated channel subfamily A member 1 Human genes 0.000 description 1
- 102100037448 Potassium voltage-gated channel subfamily A member 6 Human genes 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102100029336 Protein C12orf4 Human genes 0.000 description 1
- 102100031535 RAD51-associated protein 1 Human genes 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- MGSKVZWGBWPBTF-UHFFFAOYSA-N aebsf Chemical compound NCCC1=CC=C(S(F)(=O)=O)C=C1 MGSKVZWGBWPBTF-UHFFFAOYSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 238000012197 amplification kit Methods 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 238000003452 antibody preparation method Methods 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000012098 association analyses Methods 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 239000013602 bacteriophage vector Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037118 bone strength Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004900 c-terminal fragment Anatomy 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000022811 deglycosylation Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 229950006137 dexfosfoserine Drugs 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000004821 effect on bone Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229960000555 fenyramidol Drugs 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- TVZISJTYELEYPI-UHFFFAOYSA-N hypodiphosphoric acid Chemical class OP(O)(=O)P(O)(O)=O TVZISJTYELEYPI-UHFFFAOYSA-N 0.000 description 1
- 208000011111 hypophosphatemic rickets Diseases 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000982 limb bud Anatomy 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000000177 oncogenetic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000028776 osteoblastic osteosarcoma Diseases 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 230000003256 osteocytic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000007030 peptide scission Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- USRGIUJOYOXOQJ-GBXIJSLDSA-N phosphothreonine Chemical compound OP(=O)(O)O[C@H](C)[C@H](N)C(O)=O USRGIUJOYOXOQJ-GBXIJSLDSA-N 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 239000004848 polyfunctional curative Substances 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 230000005664 protein glycosylation in endoplasmic reticulum Effects 0.000 description 1
- 102000021581 protein kinase A binding proteins Human genes 0.000 description 1
- 108091012392 protein kinase A binding proteins Proteins 0.000 description 1
- 230000007026 protein scission Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 230000002037 soft tissue calcification Effects 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 230000001173 tumoral effect Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Pathology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Neurology (AREA)
Abstract
Description
전체 이름 | 3문자 코드 | 1문자 코드 |
아스파르트산 | Asp | D |
글루탐산 | Glu | E |
리신 | Lys | K |
아르기닌 | Arg | R |
히스티딘 | His | H |
티로신 | Tyr | Y |
시스테인 | Cys | C |
아스파라긴 | Asn | N |
글루타민 | Gln | Q |
세린 | Ser | S |
쓰레오닌 | Thr | T |
글리신 | Gly | G |
알라닌 | Ala | A |
발린 | Val | V |
루이신 | Leu | L |
이소루이신 | Ile | I |
메티오닌 | Met | M |
프롤린 | Pro | P |
페닐알라닌 | Phe | F |
트립토판 | Trp | W |
Acc 번호 | 유전자 기호 | ORF(aa) | 엑손 | pter-qter | 다형성 |
M90813 | CCND2 | 289 | |||
AJ272206* | C12orf5 | 270 | 6 | 정방향 | 716C/T(T293M) |
AF263537 | FGF23 | 251 | 3 | 역방향 | |
X63454 | FGF6 | 198 | 3 | 역방향 | |
AJ272205 | C12orf4 | 552 | 14 | 역방향 | |
AF006259 | PIR51 | 335 | 9 | 정방향 | |
AF263541* | DYRK4 | >541 | >11 | 정방향 | 351C/T(V117V)632A/G(M211S)1041C/T(A347A) |
AF093408* | AKAP3 | 853 | 5 | 역방향 | |
AF050641 | NDUFA9 | 377 | 11 | 정방향 | |
AJ271385* | GALNT8 | 637 | 11 | 정방향 | 800A/G(E267G) |
X17622 | KCNA6 | 529 | 1 | 정방향 | |
L02750 | KCNA1 | 495 | 1 | 정방향 |
프라이머 명/서열 | 프라이머 방향 | 서열 (5'-3') |
5'FGF23 프라이머 (서열 6) | 정방향 | CGGGATCCACGATGTTGG |
3'FGF23 프라이머 (서열 7) | 역방향 | GGAATTCCTAGATGAACT |
R176Q (G527A) (서열 8) | 정방향 | ATACCACGGCAGCACAC |
R176Q (G527A) (서열 9) | 역방향 | CCGGGTGTGCTGCCGTG |
R179W (C535T) (서열 10) | 정방향 | GCGGCACACCTGGAGCG |
R179W (C535T) (서열 11) | 역방향 | TCGGCGCTCCAGGTGTGC |
R179Q (G536A) (서열 12) | 정방향 | CGGCACACCCAGAGCGC |
R179W (G536A) (서열 13) | 역방향 | CTCGGCGCTCTGGGTGTG |
Claims (83)
- 섬유아세포 성장 인자-23 (FGF23)을 코딩하는 단리된 핵산 또는 그의 돌연변이체, 변이체, 동족체 또는 단편.
- 서열 1 및 서열 3 중 적어도 하나의 핵산 서열과 약 50% 이상의 서열 동일성을 공유하는, 섬유아세포 성장 인자-23 (FGF23)을 코딩하는 단리된 핵산.
- 서열 2 및 서열 4 중 적어도 하나의 아미노산 서열과 40% 이상의 서열 동일성을 공유하는 아미노산 서열을 갖는 폴리펩티드를 코딩하는, 섬유아세포 성장 인자-23 (FGF23)을 코딩하는 단리된 핵산.
- DSMZ 기탁 번호 제DSM 13530호로 기탁된 단리된 핵산.
- 제1항에 있어서, 공유적으로 연결된 태그 폴리펩티드를 코딩하는 핵산을 추가로 포함하는 단리된 핵산.
- 제5항에 있어서, 상기 태그 폴리펩티드가 myc 태그 폴리펩티드, 글루타티온-S-트랜스퍼라제 태그 폴리펩티드, 녹색 형광 단백질 태그 폴리펩티드, myc-피루베이트 키나제 태그 폴리펩티드, His6 태그 폴리펩티드, 인플루엔자 바이러스 헤마글루티닌 태그 폴리펩티드, 플래그 태그 폴리펩티드 및 말토스 결합 단백질 태그 폴리펩티드로 이루어진 군으로부터 선택되는 것인 단리된 핵산.
- 제1항에 있어서, 작동가능하게 연결된 프로모터/조절 서열을 지정하는 핵산을 추가로 포함하는 단리된 핵산.
- 제1항의 단리된 핵산을 포함하는 벡터.
- 제8항에 있어서, 작동가능하게 연결된 프로모터/조절 서열을 지정하는 핵산을 추가로 포함하는 벡터.
- 제1항의 단리된 핵산을 포함하는 재조합 세포.
- 제8항의 벡터를 포함하는 재조합 세포.
- 섬유아세포 성장 인자-23 (FGF23)을 코딩하는 핵산에 상보적이며 안티센스 방향으로 존재하는 단리된 핵산 또는 그의 돌연변이체, 변이체, 동족체 또는 단편.
- 제12항에 있어서, 서열 1 및 서열 3 중 적어도 하나의 서열을 갖는 핵산과 상보적인 핵산과 50% 이상의 서열 동일성을 공유하는 단리된 핵산.
- 제12항의 단리된 핵산을 포함하는 벡터.
- 제14항에 있어서, 작동가능하게 연결된 프로모터/조절 서열을 지정하는 핵산을 추가로 포함하는 벡터.
- 제12항의 단리된 핵산을 포함하는 재조합 세포.
- 섬유아세포 성장 인자-23 (FGF23)을 코딩하는 단리된 핵산 또는 그의 돌연변이체, 변이체, 동족체 또는 단편을 포함하는 유전자변형 (transgenic) 비인간 포유동물.
- 섬유아세포 성장 인자-23 (FGF23) 또는 그의 돌연변이체, 변이체, 동족체 또는 단편을 포함하는 단리된 폴리펩티드.
- 제18항에 있어서, 상기 FGF23의 아미노산 서열이 서열 2 및 서열 4 중 적어도 하나의 아미노산 서열과 약 40% 이상의 서열 동일성을 공유하는 것인 단리된 폴리펩티드.
- 섬유아세포 성장 인자-23 (FGF23) 폴리펩티드와 특이적으로 결합하는 항체또는 그의 돌연변이체, 변이체, 동족체 또는 단편.
- 제20항에 있어서, 폴리클로날 항체, 모노클로날 항체, 인간화 항체, 키메라 항체 및 합성 항체로 이루어진 군으로부터 선택되는 항체.
- 섬유아세포 성장 인자-23 (FGF23)을 코딩하며, 돌연변이를 포함하는 단리된 핵산.
- 제22항에 있어서, 상기 돌연변이가 상기 FGF23에 대하여 증가된 안정성을 부여하는 것인 단리된 핵산.
- 제22항에 있어서, 상기 돌연변이가 서열 2의 아미노산 176 (아르기닌)을 코딩하는 핵산에서의 돌연변이 및 서열 2의 아미노산 179 (아르기닌)를 코딩하는 핵산에서의 돌연변이로 이루어진 군으로부터 선택되는 것인 단리된 핵산.
- 돌연변이를 포함하는, 단리된 섬유아세포 성장 인자-23 (FGF23) 폴리펩티드.
- 섬유아세포 성장 인자-23 (FGF23)에 대하여 증가된 안정성을 부여하는 돌연변이를 포함하는 FGF23 폴리펩티드.
- 제26항에 있어서, 상기 돌연변이가 서열 2의 아미노산 176 (아르기닌)에서의 돌연변이 및 서열 2의 아미노산 179 (아르기닌)에서의 돌연변이로 이루어진 군으로부터 선택되는 것인 단리된 폴리펩티드.
- FGF23 폴리펩티드를 코딩하는 mRNA의 수준을 감소시키는 분자, FGF23 폴리펩티드의 수준을 감소시키는 분자 및 FGF23의 생물학적 활성을 감소시키는 분자로 이루어진 군으로부터 선택되는 섬유아세포 성장 인자-23 (FGF23) 억제제.
- 제28항에 있어서, 안티센스 핵산, 리보자임, 항체, 펩티드 및 펩티드모방체로 이루어진 군으로부터 선택되는 억제제.
- 제28항에 있어서, FGF23과 특이적으로 결합하는 항체 및 FGF23 수용체와 특이적으로 결합하는 항체로 이루어진 군으로부터 선택되는 항체인 억제제.
- 제28항에 있어서, FGF23 폴리펩티드를 코딩하는 상기 mRNA의 수준을 RNA 간섭에 의해 감소시키는 이중 가닥 RNA인 억제제.
- 제1항의 단리된 핵산 및 제약상 허용되는 담체를 포함하는 조성물.
- 제12항의 단리된 핵산 및 제약상 허용되는 담체를 포함하는 조성물.
- 제18항의 단리된 폴리펩티드 및 제약상 허용되는 담체를 포함하는 조성물.
- 제20항의 항체 및 제약상 허용되는 담체를 포함하는 조성물.
- 제22항의 단리된 핵산 및 제약상 허용되는 담체를 포함하는 조성물.
- 제23항의 단리된 핵산 및 제약상 허용되는 담체를 포함하는 조성물.
- 제24항의 단리된 핵산 및 제약상 허용되는 담체를 포함하는 조성물.
- 제25항의 단리된 FGF23 폴리펩티드 및 제약상 허용되는 담체를 포함하는 조성물.
- 제26항의 단리된 FGF23 폴리펩티드 및 제약상 허용되는 담체를 포함하는 조성물.
- 제27항의 단리된 FGF23 폴리펩티드 및 제약상 허용되는 담체를 포함하는 조성물.
- 제28항의 억제제 및 제약상 허용되는 담체를 포함하는 조성물.
- (a) 섬유아세포 성장 인자-23 (FGF23)의 생물학적 활성을 갖는 단리된 단백질이 발현되는 조건하에 제11항의 재조합 세포를 배양하는 단계; 및 (b) 상기 단백질을 회수하는 단계를 포함하는, 상기 단백질의 제조 방법.
- (a) 포유동물로부터 생물학적 샘플을 얻는 단계; 및 (b) 이 생물학적 샘플을, 섬유아세포 성장 인자-23 (FGF23)을 코딩하는 핵산에서의 돌연변이의 존재 또는 부재를 검출하는 시약과 접촉시키는 단계를 포함하며, 여기서 상기 돌연변이의 존재에 의해 상기 포유동물이 저인산혈성 질환에 걸렸음을 알 수 있고, 이에 따라 상기 포유동물에서 저인산혈성 질환을 진단하는 것인, 포유동물 저인산혈성 질환의 진단 방법.
- 제44항에 있어서, 상기 저인산혈성 질환이 상염색체 우성 저인산혈성 구루병 (ADHR)인 방법.
- 제44항에 있어서, 상기 생물학적 샘플이 혈액 및 소변으로 이루어진 군으로부터 선택되는 것인 방법.
- 제44항에 있어서, 상기 시약이 핵산인 방법.
- 제44항에 있어서, 상기 시약이 검출가능하게 표지된 것인 방법.
- 제44항에 있어서, 상기 시약이 방사성동위원소, 생물발광 화합물, 화학발광 화합물, 형광 화합물, 금속 킬레이트 및 효소로 이루어진 군으로부터 선택되는 표지로 검출가능하게 표지된 것인 방법.
- (a) 포유동물로부터 생물학적 샘플을 얻는 단계; 및 (b) 이 생물학적 샘플을, 섬유아세포 성장 인자-23 (FGF23) 폴리펩티드의 돌연변이체 형태의 존재 또는 부재를 검출하는 시약과 접촉시키는 단계를 포함하며, 여기서 FGF23 폴리펩티드의 상기 돌연변이체 형태의 존재에 의해 상기 포유동물이 저인산혈성 질환에 걸렸음을 알 수 있고, 이에 따라 상기 포유동물에서 저인산혈성 질환을 진단하는 것인, 포유동물 저인산혈성 질환의 진단 방법.
- 제50항에 있어서, 상기 저인산혈성 질환이 상염색체 우성 저인산혈성 구루병 (ADHR)인 방법.
- 제50항에 있어서, 상기 생물학적 샘플이 혈액 및 소변으로 이루어진 군으로부터 선택되는 것인 방법.
- 제50항에 있어서, 상기 시약이 항체인 방법.
- (a) 포유동물로부터 생물학적 샘플을 얻는 단계; 및 (b) 이 생물학적 샘플을, 샘플 중 섬유아세포 성장 인자-23 (FGF23) 폴리펩티드의 수준을 검출하는 시약과 접촉시키는 단계를 포함하며, 여기서 대조군 포유동물로부터 얻어진 샘플 중 FGF23 폴리펩티드의 수준과 비교해서 상기 샘플 중 FGF23 폴리펩티드의 수준이 증가된 것에 의해 상기 포유동물이 저인산혈성 질환에 걸렸음을 알 수 있고, 이에 따라 상기 포유동물에서 저인산혈성 질환을 진단하는 것인, 포유동물 저인산혈성 질환의 진단 방법.
- 제54항에 있어서, 상기 저인산혈성 질환이 X-연관 유전성 구루병 (XLH), 유전성 저인산혈성 구루병 (HHRH), 저인산혈성 골 질환 (HBD), 상염색체 우성 저인산혈성 구루병 (ADHR), 종양 유도성 골연화증, 표피 모반 증후군, 섬유성 이형성증 및 신결석증으로 이루어진 군으로부터 선택되는 것인 방법.
- 제54항에 있어서, 상기 생물학적 샘플이 혈액 및 소변으로 이루어진 군으로부터 선택되는 것인 방법.
- 제54항에 있어서, 상기 시약이 FGF23 항체인 방법.
- 제54항에 있어서, 상기 시약이 검출가능하게 표지된 것인 방법.
- 제54항에 있어서, 상기 시약이 방사성동위원소, 생물발광 화합물, 화학발광 화합물, 형광 화합물, 금속 킬레이트 및 효소로 이루어진 군으로부터 선택되는 표지로 검출가능하게 표지된 것인 방법.
- (a) 대상으로부터 종양 샘플을 얻는 단계; 및 (b) 이 종양에서 FGF23의 발현 또는 그의 결핍을 검출하는 단계를 포함하며, FGF23의 발현에 의해 상기 대상이 종양 유도성 골연화증에 걸렸음을 알 수 있는 것인, 종양 유도성 골연화증의 진단 방법.
- 저인산혈성 질환을 앓는 포유동물에게, 이 포유동물에서 FGF23 폴리펩티드를 코딩하는 mRNA의 수준을 감소시키는 억제제, 상기 포유동물에서 FGF23 폴리펩티드의 수준을 감소시키는 억제제, 및 상기 포유동물의 FGF23의 생물학적 활성 억제제로 이루어진 군으로부터 선택되는 섬유아세포 성장 인자-23 (FGF23) 억제제를 치료 유효량 투여하는 것을 포함하는, 포유동물 저인산혈성 질환의 치료 방법.
- 제61항에 있어서, 상기 저인산혈성 질환이 X-연관 유전성 구루병 (XLH), 유전성 저인산혈성 구루병 (HHRH), 저인산혈성 골 질환 (HBD), 상염색체 우성 저인산혈성 구루병 (ADHR), 종양 유도성 골연화증, 표피 모반 증후군, 섬유성 이형성증및 신결석증으로 이루어진 군으로부터 선택되는 것인 방법.
- 제61항에 있어서, 상기 억제제가 안티센스 핵산, 리보자임, 항체, 펩티드 및 펩티드모방체로 이루어진 군으로부터 선택되는 것인 방법.
- 고인산혈성 질환을 앓는 포유동물에게 섬유아세포 성장 인자-23 (FGF23)을 코딩하는 단리된 핵산을 치료 유효량 투여하는 것을 포함하는, 포유동물 고인산혈성 질환의 치료 방법.
- 제64항에 있어서, 상기 단리된 핵산이 그에 의해 코딩되는 FGF23 폴리펩티드에 증가된 안정성을 부여하는 돌연변이를 포함하는 것인 방법.
- 제64항에 있어서, 상기 고인산혈성 질환이 경증 신부전증 및 종양성 석회증으로 이루어진 군으로부터 선택되는 것인 방법.
- 고인산혈성 질환을 앓는 포유동물에게 단리된 섬유아세포 성장 인자-23 (FGF23) 폴리펩티드를 치료 유효량 투여하는 것을 포함하는, 포유동물 고인산혈성 질환의 치료 방법.
- 제67항에 있어서, 상기 단리된 FGF23 폴리펩티드가 이 폴리펩티드에 증가된안전성을 부여하는 돌연변이를 포함하는 것인 방법.
- 제67항에 있어서, 상기 고인산혈성 질환이 경증 신부전증 및 종양성 석회증으로 이루어진 군으로부터 선택되는 것인 방법.
- 고인산혈성 질환을 앓는 포유동물에게, 이 동물에서 섬유아세포 성장 인자-23 (FGF23) 폴리펩티드의 수준을 증가시키는 시약을 치료 유효량 투여하는 것을 포함하는, 포유동물 고인산혈성 질환의 치료 방법.
- 제70항에 있어서, 상기 시약이 상기 FGF23 폴리펩티드의 분해를 억제하는 것인 방법.
- 제70항에 있어서, 상기 고인산혈성 질환이 경증 신부전증 및 종양성 석회증으로 이루어진 군으로부터 선택되는 것인 방법.
- 고인산혈성 질환을 앓는 포유동물에게, 섬유아세포 성장 인자-23 (FGF23)을 코딩하는 단리된 핵산을 포함하는 세포 집단을 치료 유효량 투여하는 것을 포함하는, 포유동물 고인산혈성 질환의 치료 방법.
- 제73항에 있어서, 상기 단리된 핵산이 그에 의해 코딩되는 상기 FGF23에 증가된 안정성을 부여하는 돌연변이를 포함하는 것인 방법.
- 제73항에 있어서, 상기 저인산혈성 질환이 경증 신부전증 및 종양성 석회증으로 이루어진 군으로부터 선택되는 것인 방법.
- 포유동물에게, 섬유아세포 성장 인자-23 (FGF23), 또는 상기 포유동물에서 FGF23 폴리펩티드의 수준을 증가시키는 시약을 치료 유효량 투여하는 것을 포함하는, 포유동물 골다공증의 치료 방법.
- 포유동물에게, 섬유아세포 성장 인자-23 (FGF23), 또는 FGF23 폴리펩티드의 수준을 증가시키는 시약을 치료 유효량 투여하는 것을 포함하는, 상기 포유동물의 동맥 또는 연조직내 칼슘 및 포스페이트의 침착을 포함하는 증상의 치료 방법.
- 제77항에 있어서, 상기 증상이 피부근염인 방법.
- 관상동맥 질환을 앓는 포유동물의 관상동맥 세포에 섬유아세포 성장 인자-23 (FGF23)을 코딩하는 핵산을 투여하는 것을 포함하는, 포유동물 관상동맥 질환의 치료 방법.
- 섬유아세포 성장 인자-23 (FGF23)을 코딩하는 핵산 서열에서의 돌연변이의존재 또는 부재를 검출하는 시약, 및 추가로 어플리케이터 (applicator) 및 사용 지침을 포함하며, 여기서 상기 돌연변이의 존재에 의해 상기 포유동물이 저인산혈성 질환에 걸렸음을 알 수 있는 것인, 포유동물 저인산혈성 질환의 진단용 키트.
- 섬유아세포 성장 인자-23 (FGF23) 폴리펩티드의 수준을 검출하는 시약, 및 추가로 어플리케이터 및 사용 지침을 포함하며, 여기서 상기 FGF23 폴리펩티드의 증가된 수준에 의해 상기 포유동물이 저인산혈성 질환에 걸렸음을 알 수 있는 것인, 포유동물 저인산혈성 질환의 진단용 키트.
- 섬유아세포 성장 인자-23 (FGF23) 폴리펩티드의 돌연변이체 형태의 존재 또는 부재를 검출하는 시약, 및 추가로 어플리케이터 및 사용 지침을 포함하며, 여기서 상기 FGF23의 돌연변이체 형태의 존재에 의해 상기 포유동물이 저인산혈성 질환에 걸렸음을 알 수 있는 것인, 포유동물 저인산혈성 질환의 진단용 키트.
- 제24항에 있어서, 상기 돌연변이가 서열 1에 있어서 527G>A, 535C>T 및 536G>A로 이루어진 군으로부터 선택되는 것인 단리된 핵산.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21913700P | 2000-07-19 | 2000-07-19 | |
US60/219,137 | 2000-07-19 | ||
PCT/US2001/021738 WO2002008271A1 (en) | 2000-07-19 | 2001-07-10 | Novel fibroblast growth factor (fgf23) and methods for use |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020097006051A Division KR20090036151A (ko) | 2000-07-19 | 2001-07-10 | 신규 섬유아세포 성장 인자 (fgf23) 및 그의 이용 방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20030029111A true KR20030029111A (ko) | 2003-04-11 |
KR100924183B1 KR100924183B1 (ko) | 2009-10-28 |
Family
ID=22818027
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020097006051A KR20090036151A (ko) | 2000-07-19 | 2001-07-10 | 신규 섬유아세포 성장 인자 (fgf23) 및 그의 이용 방법 |
KR1020037000821A KR100924183B1 (ko) | 2000-07-19 | 2003-01-18 | 신규 섬유아세포 성장 인자 (fgf23) 및 그의 이용 방법 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020097006051A KR20090036151A (ko) | 2000-07-19 | 2001-07-10 | 신규 섬유아세포 성장 인자 (fgf23) 및 그의 이용 방법 |
Country Status (11)
Country | Link |
---|---|
US (5) | US7223563B2 (ko) |
EP (2) | EP1303536B1 (ko) |
JP (2) | JP2004504063A (ko) |
KR (2) | KR20090036151A (ko) |
CN (1) | CN1446227B (ko) |
AT (1) | ATE461213T1 (ko) |
AU (2) | AU7332301A (ko) |
CA (1) | CA2418215A1 (ko) |
DE (1) | DE60141582D1 (ko) |
ES (1) | ES2340662T3 (ko) |
WO (1) | WO2002008271A1 (ko) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020137890A1 (en) * | 1997-03-31 | 2002-09-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20060160181A1 (en) * | 2000-02-15 | 2006-07-20 | Amgen Inc. | Fibroblast Growth Factor-23 molecules and uses thereof |
EP2075255A1 (en) * | 2000-03-08 | 2009-07-01 | Novartis Vaccines and Diagnostics, Inc. | Human FGF-23 gene and gene expression products |
CN101275136A (zh) * | 2000-08-11 | 2008-10-01 | 麒麟医药株式会社 | 调节磷酸代谢,钙代谢,钙化和维生素d代谢的多肽及其编码dna |
US6838264B2 (en) | 2000-12-05 | 2005-01-04 | Immutopics, Inc. | Antibodies and peptide antigens for producing antibodies having a selective binding specificity to bioactive intact parathyroid hormone (PTH) 1-84 |
US7226749B2 (en) | 2000-12-05 | 2007-06-05 | Zahradnik Richard J | Antibodies and peptide antigens for producing antibodies having a selective binding specificity to bioactive intact parathyroid hormone (PTH) 1-84 |
KR20030074678A (ko) * | 2000-12-26 | 2003-09-19 | 추가이 세이야쿠 가부시키가이샤 | 혈중 인농도를 저하시키는 인간 fgf23 단백질 변이체 |
US20040171825A1 (en) * | 2001-04-26 | 2004-09-02 | Lydie Bougueleret | Human fibroblast growth factor-related compositions |
ES2331414T3 (es) | 2001-12-28 | 2010-01-04 | Kyowa Hakko Kirin Co Ltd | Anticuerpos contra el factor 23 de crecimiento de fibroblastos. |
US7094551B2 (en) | 2002-09-17 | 2006-08-22 | Zahradnik Richard J | Immunoassays, assay methods, antibodies and method of creating antibodies for detecting FGF-23 |
EP1682665B1 (en) * | 2003-11-07 | 2011-04-27 | Novartis AG | Use of fibroblast growth factor fragments |
IL161886A0 (en) * | 2004-05-09 | 2005-11-20 | Technion Res & Dev Foundation | Development of inducers of udp-n-acetyl-alphad-galactosamine: polypeptide n-acetylgalactosami-nyltransferase 3(ppgantase |
WO2005108607A1 (en) * | 2004-05-09 | 2005-11-17 | Technion Research & Development Foundation Ltd. | Compositions and methods for treating disorders associated with abnormal phosphate metabolism |
US20060236220A1 (en) * | 2005-04-18 | 2006-10-19 | Clearplay, Inc. | Apparatus, System and Method for Associating One or More Filter Files with a Particular Multimedia Presentation |
KR100760525B1 (ko) * | 2006-04-13 | 2007-10-04 | 김재만 | 병원성 미생물의 무증폭 다중 정량 검출킷트 및 검출방법 |
US8012694B2 (en) | 2006-09-14 | 2011-09-06 | Immutopics, Inc. | Assay for the detection of phosphorylated PTH |
EP2115168A1 (en) | 2007-01-22 | 2009-11-11 | Medizinische Universität Innsbruck | Novel markers for chronic kidney disease |
US7883705B2 (en) * | 2007-02-14 | 2011-02-08 | Kyowa Hakko Kirin Co., Ltd. | Anti FGF23 antibody and a pharmaceutical composition comprising the same |
US20110183434A1 (en) * | 2008-01-17 | 2011-07-28 | Myles Wolf | Diagnostic methods and kits using fibroblast growth factor-23 |
TW200936156A (en) | 2008-01-28 | 2009-09-01 | Novartis Ag | Methods and compositions using Klotho-FGF fusion polypeptides |
US8420088B2 (en) | 2008-01-28 | 2013-04-16 | Novartis Ag | Methods and compositions using FGF23 fusion polypeptides |
RU2010148531A (ru) * | 2008-04-29 | 2012-06-10 | Новартис АГ (CH) | Способы мониторинга модуляции киназной активности рецептора фактора роста фибробластов и применения указанных способов |
US8889621B2 (en) | 2009-10-30 | 2014-11-18 | New York University | Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia |
US20110195077A1 (en) | 2010-01-29 | 2011-08-11 | Novartis Ag | Methods and compositions using fgf23 fusion ppolypeptides |
US10422796B2 (en) | 2010-08-31 | 2019-09-24 | Kyowa Medex Co., Ltd. | Method for measuring fibroblast growth factor-23 and reagent therefor |
WO2012055096A1 (zh) * | 2010-10-27 | 2012-05-03 | 温州医学院生物与天然药物开发中心有限公司 | 抗fgf-23抗体的制备方法及用途 |
EP2723391B1 (en) | 2011-06-24 | 2018-06-13 | University of Miami | Fibroblast growth factor receptor inhibition for the treatment of disease |
CN105601748B (zh) | 2011-07-01 | 2021-08-27 | 恩格姆生物制药公司 | 用于代谢病症和疾病治疗的组合物、应用和方法 |
WO2013027191A1 (en) | 2011-08-25 | 2013-02-28 | Novartis Ag | Methods and compositions using fgf23 fusion polypeptides |
US9657075B2 (en) | 2012-06-07 | 2017-05-23 | New York University | Chimeric fibroblast growth factor 23 proteins and methods of use |
US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
WO2014085365A2 (en) | 2012-11-28 | 2014-06-05 | Ngm Biopharmaceuticals, Inc. | Compositions and methods for treatment of metabolic disorders and diseases |
US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
CN105008548B (zh) | 2012-12-27 | 2020-11-27 | 恩格姆生物制药公司 | 用于调节胆汁酸体内稳态以及治疗胆汁酸紊乱和疾病的方法 |
WO2014130659A1 (en) | 2013-02-22 | 2014-08-28 | New York University | Chimeric fibroblast growth factor 23 proteins and methods of use |
US10745668B2 (en) * | 2013-09-20 | 2020-08-18 | Lonza Ltd | Methods for nuclear reprogramming of cells |
NZ718962A (en) | 2013-10-28 | 2019-12-20 | Ngm Biopharmaceuticals Inc | Cancer models and associated methods |
ES2808340T3 (es) | 2014-01-24 | 2021-02-26 | Ngm Biopharmaceuticals Inc | Anticuerpos que se unen al dominio de beta klotho 2 y procedimientos de uso de los mismos |
AU2015237176A1 (en) | 2014-03-28 | 2016-10-20 | New York University | FGF23 fusion proteins |
US10398758B2 (en) | 2014-05-28 | 2019-09-03 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions |
ES2851674T3 (es) * | 2014-06-09 | 2021-09-08 | Ultragenyx Pharmaceutical Inc | Control efectivo y eficaz de fosfato sérico para una formación ósea óptima |
WO2015195509A2 (en) | 2014-06-16 | 2015-12-23 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
IL251834B2 (en) | 2014-10-23 | 2023-09-01 | Ngm Biopharmaceuticals Inc | Pharmaceutical compositions containing peptide variants and methods of using them |
WO2016073855A1 (en) | 2014-11-07 | 2016-05-12 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
WO2016088059A1 (en) | 2014-12-04 | 2016-06-09 | Novartis Ag | Methods and compositions using klotho variant polypeptides |
CN105699664A (zh) * | 2015-04-13 | 2016-06-22 | 陈柏龄 | Fgf23检测试剂盒及其制备方法 |
CN108474009B (zh) * | 2015-06-25 | 2022-10-04 | 阿迈瑞斯公司 | 麦芽糖依赖性降解决定子、麦芽糖响应型启动子、稳定化构建体及其在生成非分解代谢化合物中的用途 |
US10800843B2 (en) | 2015-07-29 | 2020-10-13 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins |
CA3082794A1 (en) | 2015-11-09 | 2017-05-18 | Ngm Biopharmaceuticals Inc. | Methods for treatment of bile acid-related disorders |
EP3503882A4 (en) | 2016-08-26 | 2020-07-29 | NGM Biopharmaceuticals, Inc. | METHOD FOR TREATING FIBROBLAST GROWTH FACTOR-19-MEDIATED CARCINOMAS AND TUMORS |
WO2018181342A1 (ja) * | 2017-03-28 | 2018-10-04 | 味の素株式会社 | 未分化維持培地添加剤 |
WO2018221544A1 (ja) | 2017-05-31 | 2018-12-06 | 協和メデックス株式会社 | 線維芽細胞増殖因子-23の測定方法、測定試薬及び測定キット |
WO2020047475A1 (en) * | 2018-08-30 | 2020-03-05 | The Uab Research Foundation | Drug screening for fgf23-fgfr4 inhibitors |
TW202102261A (zh) * | 2019-03-29 | 2021-01-16 | 美商艾特加有限責任公司 | Fgf23之抗體分子及其用途 |
BR112021020888A2 (pt) * | 2019-04-19 | 2021-12-21 | Genethon | Terapia gênica de doenças hipofosfatêmicas relacionadas a fator de crescimento fibroblástico 23 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4160452A (en) | 1977-04-07 | 1979-07-10 | Alza Corporation | Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina |
US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
WO1994017810A1 (en) | 1993-02-12 | 1994-08-18 | The Wistar Institute Of Anatomy And Biology | Recombinant cytomegalovirus vaccine |
EP0708658A4 (en) | 1993-04-16 | 1997-05-21 | Wistar Inst | VACCINE CONTAINING A RECOMBINANT CYTOMEGALOVIRUS |
WO2000073454A1 (en) | 1999-06-02 | 2000-12-07 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US5693775A (en) * | 1995-05-12 | 1997-12-02 | The Johns Hopkins University School Of Medicine | Fibroblast growth factor homologous factor-1 (FHF-1) and methods of use |
EP1661997A1 (en) * | 1999-12-01 | 2006-05-31 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
JP2003516150A (ja) * | 1999-12-08 | 2003-05-13 | ジェンセット | 潜在性分泌タンパク質をコードする全長ヒトcDNA |
EP1246843A1 (en) | 2000-01-05 | 2002-10-09 | ZymoGenetics, Inc. | Novel fgf homolog zfgf12 |
US20030149238A1 (en) | 2000-02-14 | 2003-08-07 | Pankaj Agarwal | Novel compounds |
AU3976701A (en) * | 2000-02-15 | 2001-08-27 | Amgen, Inc. | Fibroblast growth factor-23 molecules and uses thereof |
EP2075255A1 (en) | 2000-03-08 | 2009-07-01 | Novartis Vaccines and Diagnostics, Inc. | Human FGF-23 gene and gene expression products |
WO2002076467A1 (en) * | 2001-03-22 | 2002-10-03 | Genzyme Corporation | Compositions and methods to regulate bone and mineral metabolism |
-
2001
- 2001-07-10 EP EP01952590A patent/EP1303536B1/en not_active Expired - Lifetime
- 2001-07-10 KR KR1020097006051A patent/KR20090036151A/ko not_active Application Discontinuation
- 2001-07-10 CN CN018140572A patent/CN1446227B/zh not_active Expired - Lifetime
- 2001-07-10 AT AT01952590T patent/ATE461213T1/de not_active IP Right Cessation
- 2001-07-10 AU AU7332301A patent/AU7332301A/xx active Pending
- 2001-07-10 EP EP10001442A patent/EP2184296A1/en not_active Withdrawn
- 2001-07-10 DE DE60141582T patent/DE60141582D1/de not_active Expired - Lifetime
- 2001-07-10 AU AU2001273323A patent/AU2001273323B2/en not_active Expired
- 2001-07-10 US US09/901,938 patent/US7223563B2/en not_active Expired - Lifetime
- 2001-07-10 WO PCT/US2001/021738 patent/WO2002008271A1/en active IP Right Grant
- 2001-07-10 JP JP2002514175A patent/JP2004504063A/ja active Pending
- 2001-07-10 CA CA002418215A patent/CA2418215A1/en not_active Abandoned
- 2001-07-10 ES ES01952590T patent/ES2340662T3/es not_active Expired - Lifetime
-
2003
- 2003-01-18 KR KR1020037000821A patent/KR100924183B1/ko active IP Right Grant
- 2003-03-04 US US10/379,334 patent/US7314618B2/en not_active Expired - Lifetime
-
2007
- 2007-11-07 US US11/983,137 patent/US7745406B2/en not_active Expired - Fee Related
- 2007-11-07 US US11/983,190 patent/US7947810B2/en not_active Expired - Fee Related
-
2008
- 2008-02-05 JP JP2008025528A patent/JP2008194039A/ja active Pending
-
2011
- 2011-04-11 US US13/084,203 patent/US8586317B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JP2008194039A (ja) | 2008-08-28 |
AU2001273323B2 (en) | 2005-11-10 |
US20120064544A1 (en) | 2012-03-15 |
DE60141582D1 (de) | 2010-04-29 |
WO2002008271A1 (en) | 2002-01-31 |
US8586317B2 (en) | 2013-11-19 |
KR20090036151A (ko) | 2009-04-13 |
US7947810B2 (en) | 2011-05-24 |
CN1446227B (zh) | 2011-10-05 |
EP1303536B1 (en) | 2010-03-17 |
AU7332301A (en) | 2002-02-05 |
US20090311792A1 (en) | 2009-12-17 |
US7745406B2 (en) | 2010-06-29 |
US7314618B2 (en) | 2008-01-01 |
EP1303536A1 (en) | 2003-04-23 |
KR100924183B1 (ko) | 2009-10-28 |
US20020156001A1 (en) | 2002-10-24 |
US20080241946A1 (en) | 2008-10-02 |
EP2184296A1 (en) | 2010-05-12 |
ES2340662T3 (es) | 2010-06-08 |
ATE461213T1 (de) | 2010-04-15 |
US20030181379A1 (en) | 2003-09-25 |
JP2004504063A (ja) | 2004-02-12 |
CN1446227A (zh) | 2003-10-01 |
CA2418215A1 (en) | 2002-01-31 |
EP1303536A4 (en) | 2005-01-05 |
US7223563B2 (en) | 2007-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100924183B1 (ko) | 신규 섬유아세포 성장 인자 (fgf23) 및 그의 이용 방법 | |
AU2001273323A1 (en) | Novel fibroblast growth factor (FGF23) and methods for use | |
US6525018B1 (en) | Treating eye disorders using intestinal trefoil proteins | |
JP2001524824A (ja) | Crspタンパク質(システインに富む分泌性タンパク質)、それらをコードする核酸分子およびその用途 | |
US6630325B1 (en) | Compositions, methods and kits relating to remodel | |
WO1998046756A1 (en) | Secreted protein ssp-1 compositions and therapeutic and diagnostic uses therefor | |
JP2002530058A (ja) | 31個のヒト分泌タンパク質 | |
US20050049212A1 (en) | Bestrophin and bestrophin homologous proteins involved in the regulation of energy homeostasis | |
US20040242515A1 (en) | Trp1, mct, or ftz-f1 homologous proteins involved in the regulation of energy home-ostasis | |
JP2004514404A (ja) | 血管形成関連タンパク質及びこれをコードする核酸 | |
US6537554B1 (en) | Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis | |
US20030125296A1 (en) | Insulin-responsive DNA binding protein-1 and methods to regulate insulin-responsive genes | |
US20060168667A1 (en) | Minibrain homologous proteins involved in the regulation of energy homeostasis | |
US20030104573A1 (en) | Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis | |
US20050176659A1 (en) | Endophilin homologous proteins involved in the regulation of energy homeostasis | |
JP2003052388A (ja) | 結腸特異的遺伝子およびタンパク質 | |
JP2002017379A (ja) | 神経伝達物質輸送体 | |
JP2003000246A (ja) | 松果腺特異的遺伝子−1 | |
JP2003038174A (ja) | ヒトアミン受容体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
A107 | Divisional application of patent | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121009 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20131010 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20141008 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20151007 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20161012 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20171013 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20181011 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20191010 Year of fee payment: 11 |